ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.76
0.31%
US Tech 100
18,393.20
0.41%
S&P 500
5,304.72
0.70%
US Dollar vs CAD
1.36255
-0.03%
Bitcoin
67,927.55
-2.11%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Astria Therapeutics Inc (ATXS)

  7. Astria Therapeutics Inc (ATXS) News

ATXS

Astria Therapeutics (ATXS)

Astria Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATXS
DateTimeSourceHeadlineSymbolCompany
05/24/20247:00AMBusiness WireAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceNASDAQ:ATXSAstria Therapeutics Inc
05/23/20247:00AMBusiness WireAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology CongressNASDAQ:ATXSAstria Therapeutics Inc
05/09/20243:10PMBusiness WireAstria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
05/09/20243:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATXSAstria Therapeutics Inc
05/08/20247:00AMBusiness WireAstria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual MeetingNASDAQ:ATXSAstria Therapeutics Inc
05/02/20243:00PMBusiness WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
04/09/20247:00AMBusiness WireAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsNASDAQ:ATXSAstria Therapeutics Inc
04/03/20243:10PMBusiness WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
03/25/20246:30AMBusiness WireAstria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAENASDAQ:ATXSAstria Therapeutics Inc
03/05/20243:10PMBusiness WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
03/04/20244:22PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXSAstria Therapeutics Inc
03/04/20244:20PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXSAstria Therapeutics Inc
03/04/20243:10PMBusiness WireAstria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
03/04/20243:02PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ATXSAstria Therapeutics Inc
02/20/20247:00AMBusiness WireAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual MeetingNASDAQ:ATXSAstria Therapeutics Inc
02/14/20242:48PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
02/14/20242:00PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
02/14/20247:36AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
02/12/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
02/12/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
02/12/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
02/12/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
02/12/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
02/12/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
02/06/20247:00AMBusiness WireAstria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ATXSAstria Therapeutics Inc
02/05/20243:00PMBusiness WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
01/31/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXSAstria Therapeutics Inc
01/31/20247:59AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXSAstria Therapeutics Inc
01/30/20244:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
01/30/20248:08AMBusiness WireAstria Therapeutics Announces Pricing of $125 Million Underwritten OfferingNASDAQ:ATXSAstria Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXS

Your Recent History

KOSPI
012510
Douzone Bizon
ASX
REAKOP
BIT
UV8C7D
UniCredit Bank
USOTC
BLLYF
Bluejay Mining (PK)
ASE
BLEKEDROS
Mple Kerdos REIC
USOTC
NGXXF
Ngex Minerals (QX)
LSE
69JO
Op Corp. 27
AMEX
BBVX
BOV
CSNAR137
CSNAR137 Ex:13,03
LSE
76TJ
Ashtead Cap 29s
TSXV
SBS.H
Sebastiani Ventures
ASX
JATDD
Jatcorp
USOTC
PLRBF
Pluribus Technologies (PK)
BIT
F19168
Vontobel Financial Produ...
NASDAQ
HSTM
HealthStream
AMEX
VUG
Vanguard Growth ETF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved